In-vitro fertilization (IVF) is a process of fertilization that involves combining egg with sperm in vitro. Assisted reproductive technology (ART) is associated with treatment of infertility and genetic disorders related to child conception, where IVF is the foremost effective form of ART. In 2015, as reported by the Center for Disease Control and Prevention (CDC), the U.S. reported 231,936 performed cycles of ART in 464 clinics, which resulted in 60,778 live births. In order to transfer embryos into the uterus, ART cycles comprises series of procedures, starting from ART procedure followed by ovarian stimulation and unfreezing embryos. Factors such as reproductive history, maternal age, cause of infertility, embryo status, and lifestyle factors (such as obesity, smoking, drinking alcohol, extreme caffeine consumption, drugs) are responsible concluding success rate of IVF, hence they are important to be undertaken before the IVF procedure. In-vitro fertilisation is preferred also when the patients are experiencing certain conditions such as damage or blockage of fallopian tube, ovulation disorders, premature ovarian failure, endometriosis other disorders related to infertility.
Get PDF Brochure Of This Report With Detailed Analysis @ https://www.coherentmarketinsights.com/insight/request-pdf/887
Increasing cases of PCOS- Polycystic Ovary Syndrome is expected to boost growth of the global In-vitro fertilization devices market over the forecast period. For instance, in 2016, the CDC reported, 5 million women are affected by PCOS through their reproductive age leading to infertility in the U.S. in addition to that, half the women having PCOS get affected by type 2 diabetes leading to further complications related to fertility.
Expensive treatment methods of in-vitro fertilization are expected to hinder growth of the global in-vitro fertilization devices market. For instance, according to the American Society for Reproductive Medicine (ASRM), a cycle of IVF including preliminary test, fertility medications, blood tests and ultrasound monitoring averagely costs US$ 12,400 in the U.S. Moreover, increasing demand of ART treatment such as Intra Cytoplasmic Sperm Injection (ICSI) is expected to increase the cost of IVF by US$ 1000 to 3000.
Certain risks such as low birth weight, premature delivery, multiples births, complications during egg retrieval process ovarian hyperstimulation syndrome, birth defects, miscarriage, ovarian cancer, and ectopic pregnancy risks posed by in-vitro fertilization processes are expected to hamper growth of the global in-vitro fertilization devices market.
Buy This Research Study Report For Quick Access@ https://www.coherentmarketinsights.com/insight/buy-now/887
By product type
Semen processing media
Embryo culture media
Ovum processing media
Laminar air flow instrument
Embryo cryogenic storage tank
Intra Cytoplasmic Sperm Injection (ICSI)
Embryo Freezing and Frozen Embryo Transfer (FET)
Pre-Implantation Genetic Diagnosis (PGD)
By end user
Clinical research institutes
North America is expected to witness robust growth in the in-vitro fertilization devices market. This is attributed to prevalence of infertility in the U.S. due to unhealthy habits such as excess of smoking and drinking, obesity and chronic conditions. For instance, in 2017, the Center for Disease Control and Prevention (CDC) estimated around 6.7% of women aging from 15 to 44 years are infertile and 12.1% of women have impaired fecundity in the U.S. Moreover, in 2014, CDC published Behavioral Risk Factor Surveillance System Data according to which, 52.8% women from age group of 18 to 44 years are obese, which majorly causes infertility, 19.2% women had smoking habits and 16.9% women had binge drinking habit, which are another causes of infertility in women.
Major players active in the in-vitro fertilization devices market are, CooperSurgical Inc., COOK MEDICAL INC., Merck KGaA, JXTG Holdings, Inc., Oxford Gene Technology Inc., EMD Serono,Inc., and Irvine Scientific. Vitrolife AB, Thermo Fisher Scientific Inc., Genea Biomedx, OvaScience, Inc., and Progyny, Inc.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027